Shareholders of up-and-down Dendreon Corp. received good news Thursday when company officials said the Food and Drug Administration provided encouraging news on the drug company's prostate cancer drug Provenge.
Geoff McKay, CEO of regenerative technology company Organogenesis Inc., said Gov. Deval Patrick's recent $1 billion pledge of support for life sciences was a tipping point in the Canton-based company's decision to stay in the Bay State.